Extended Antitumor Responseof a BRAF V600E Papillary Thyroid Carcinoma to Vemurafenib

Publisher： Karger

E-ISSN： 1662-6575|7|2|343-348

ISSN： 1662-6575

Source： Case Reports in Oncology, Vol.7, Iss.2, 2014-05, pp. : 343-348

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Time to re‐consider the meaning of BRAF V600E mutation in papillary thyroid carcinoma

By  

INTERNATIONAL JOURNAL OF CANCER, Vol. 137, Iss. 5, 2015-09 ,pp. : 1001-1011

John Wiley & Sons Inc

Access to resources Recommend Favorite

Absence of BRAF V600E in non‐infiltrative, non‐invasive follicular variant of papillary thyroid carcinoma

By  

HISTOPATHOLOGY, Vol. 309-0167, Iss. 4, 2015-10 ,pp. : 579-582

John Wiley & Sons Inc

Access to resources Recommend Favorite

Absence of BRAF V600E in non‐infiltrative, non‐invasive follicular variant of papillary thyroid carcinoma

By  

HISTOPATHOLOGY, Vol. 67, Iss. 4, 2015-10 ,pp. : 579-582

John Wiley & Sons Inc

Access to resources Recommend Favorite

Use of BRAF v600e immunocytochemistry on FNA direct smears of papillary thyroid carcinoma

By  

CANCER CYTOPATHOLOGY, Vol. 123, Iss. 9, 2015-09 ,pp. : 531-539

John Wiley & Sons Inc

Access to resources Recommend Favorite

Detection of BRAF c.1799T > A (p.V600E) mutation using residual routine fine‐needle aspiration specimens of papillary thyroid carcinoma

By  

DIAGNOSTIC CYTOPATHOLOGY, Vol. 43, Iss. 10, 2015-10 ,pp. : 786-790

John Wiley & Sons Inc

Access to resources Recommend Favorite